Allergy Asthma Immunol Res.  2018 May;10(3):283-284. 10.4168/aair.2018.10.3.283.

The Relevance of Nasal Cytology in the Workup of House Dust Mite-Induced Allergic Rhinitis

• Gelardi M
• Puccinelli P
• Incorvaia
• Passalacqua G
• Ciprandi G
• Italian Cometa Study Group

• KMID: 2409064
• DOI: http://doi.org/10.4168/aair.2018.10.3.283

Abstract

No abstract available.

MeSH Terms

Dust*
Rhinitis, Allergic*
Dust

Figure

• 

  Figure (A) Distribution expressed as percentage of patients with or without associated NAR. (B) Distribution expressed as percentage of patients with NARESMA (n=11), NARNE (n=6), NARMA (n=3), and NARES (n=1). NAR, nonallergic rhinitis; NARESMA, nonallergic rhinitis with eosinophils and mast cells; NARNE, nonallergic rhinitis with neutrophils; NARMA, nonallergic rhinitis with mast cells; NARES, nonallergic rhinitis with eosinophils.

Reference

1. Chen J, Zhou Y, Zhang L, Wang Y, Pepper AN, Cho SH, et al. Individualized treatment of allergic rhinitis according to nasal cytology. Allergy Asthma Immunol Res. 2017; 9:403–409.

2. Calderón MA, Bousquet J, Canonica GW, Cardell LO, Fernandez de, Kleine-Tebbe J, et al. Guideline recommendations on the use of allergen immunotherapy in house dust mite allergy: time for a change. J Allergy Clin Immunol. 2017; 140:41–52.

3. Ciprandi G, Natoli V, Puccinelli P, Incorvaia C. Italian Cometa Study Group. Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world. Allergy Asthma Clin Immunol. 2017; 13:11.

4. Gelardi M, Fiorella ML, Russo C, Fiorella R, Ciprandi G. Role of nasal cytology. Int J Immunopathol Pharmacol. 2010; 23:45–49.

5. Gelardi M, Maselli del, Fiorella ML, Fiorella R, Russo C, Soleti P, et al. Non-allergic rhinitis with eosinophils and mast cells constitutes a new severe nasal disorder. Int J Immunopathol Pharmacol. 2008; 21:325–331.

6. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013; 132:1322–1336.

7. Ciprandi G, Incorvaia C, Masieri S, Buttafava S, Frati F. The best allergen immunotherapy choice for mite allergic patients. Expert Rev Clin Immunol. 2016; 12:603–604.